As a major achievement in the treatment of diabetic retinopathy and age-related macular degeneration, the NeoVasculoStop consortium has successfully reached the milestone of Month 30, with the aim of “identifying the two best inhibitors.” Correspondingly, EYE1118 has been selected as an efficient promising lead compound and EYE1090 as the follow-up molecule by the research group led by Dr. Krisztián Kovács. This achievement marks a critical phase in the project, representing the selection of inhibitors developed for targeted disease treatment. We are optimistic about the future applications of these results in treating a complex group of diseases.
As a key player in the NeoVasculoStop project, Semmelweis University undertakes the task of examining the efficiency of the newly developed compounds in a cell culture-based system that allows for the screening of a larger number of molecules. Additionally, the university is conducting preclinical efficacy studies on rats. As a result of this work, the two inhibitors were selected.
For further details, visit the project’s official website.
Image and text: NeoVasculoStop – Institute of Translational Medicine
